22.20
+19.23%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Precipio
Its shares trade under the ticker PRPO. It has been listed since 18 July 2000. In the fiscal year to 31 December 2025, it reported revenue of $24.0m and a net loss of $363,000. At that date it held total assets of $21.3m and shareholders' equity of $14.6m.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. The company is headquartered in Omaha, Nebraska. The company went IPO on 2000-07-18. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The firm has developed a screening panel for genes in one rapid scanning panel, HemeScreen.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 18 Jul 2000
- Employees
- 61
- Website
- precipiodx.com ↗
- Head office
- 4 SCIENCE PARK, NEW HAVEN, CT, 06511
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Richard SandbergIndependent Chairman of the Board$75,030
- Mr. Ilan DanieliChief Executive Officer, Founder, Director, since 2017$462,102
- Mr. Matthew GageChief Financial Officer
- Mr. Ahmed Zaki SabetChief Operations Officer$399,056
- Dr. Ayman MohamedChief Technology Officer$403,402
- Mr. Ronald AndrewsIndependent Director$44,530
- Mr. David CohenIndependent Director$57,030
- Dr. Jeffrey CossmanIndependent Director$46,530
- Ms. Kathleen LaporteIndependent Director$54,530
- Ms. Christina ValauriIndependent Director$45,702
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Precipio's IV-Cell platform addresses selective culturing issues in cancer diagnostics.
- Precipio's HemeScreen screening panel rapidly scans multiple genes for cancer detection.
- Precipio's ICE-COLD-PCR technology enhances molecular test sensitivity for accurate diagnoses.
Weaknesses
- Precipio employs only 50 full-time employees in Omaha, Nebraska.
- Precipio's IPO date was July 18, 2000, indicating a long market presence.
- Precipio's headquarters in Omaha, Nebraska may limit access to major biotech hubs.
Opportunities
- Precipio's IV-Cell and HemeScreen technologies can expand into new cancer diagnostic markets.
- Precipio's ICE-COLD-PCR technology offers potential for global health care applications.
- Precipio can leverage its platform to enter emerging cancer diagnostics segments.
Threats
- Precipio faces competition from established cancer diagnostics firms in the Health Care sector.
- Precipio's limited employee count of 50 may hinder rapid innovation and market expansion.
- Precipio's Omaha, Nebraska location could pose challenges in attracting top biotech talent.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.